It’s no se­cret that sales of Leqem­bi have been dis­ap­point­ing.

First ap­proved in 2023, the Alzheimer’s drug from Ei­sai and Bio­gen launched short­ly af­ter Chris...

Mer­ck CEO Rob Davis said he has warned Con­gress and the Trump ad­min­is­tra­tion that if they cut off or ham­per US-Chi­na deal­mak­ing, the US could lose...

Re­ta­tru­tide, the obe­si­ty can­di­date that has shown the most pow­er­ful weight loss in late-stage tri­als, will be filed for ap­proval ear­ly next year, its de­vel­op­er...